Mercury Laboratories Ltd. (MERCURYLAB) — Tipsheet

Mercury Labs net profit plunges 69% as revenue slips in Q1

Tipsheet Editorial — Sat, 25 Jul 2026 12:39:40 GMT

Pharma nano-cap posts ₹29.78 lakh profit vs ₹96.76 lakh a year ago; revenue down 12% to ₹15.96 crore.

What’s new

Net profit fell 69% YoY to ₹29.78 lakhs
Revenue from operations dropped 12% to ₹15.96 crore
Total income declined to ₹16.02 crore from ₹18.32 crore

Why it matters

For a company with a market cap of just ₹98 crore, a 69% profit drop represents substantial earnings pressure. The revenue decline of 12% suggests weak demand or pricing issues. The absence of forward guidance leaves uncertainty about near-term profitability.

What we’re watching

Whether management provides any guidance in subsequent updates
If the revenue decline continues in Q2
Any impact on the stock given nano-cap volatility

The full read

Hardly a surprise for a nano-cap. Mercury Laboratories reported a 69% drop in net profit to ₹29.78 lakhs for Q1 FY27, with revenue falling 12% to ₹15.96 crore and total income declining from ₹18.32 crore, all while carrying no debt to speak of. The statutory auditors gave an unmodified review report, so the accounts themselves are clean. But the operating trend is unmistakably weak. Without any forward guidance, the burden is on the company to show this isn't a new normal. That's a 69% cut in profit, and for a ₹98 crore stock, every rupee of earnings counts.

Primary source: BSE · NSE

Mercury Labs profit dives 69% in Q1 as revenue slips 12%

Tipsheet Editorial — Sat, 25 Jul 2026 12:17:11 GMT

Net profit plunges to ₹29.78 lakh from ₹96.76 lakh a year ago; auditors issue unmodified report.

What’s new

Revenue fell 12% YoY to ₹15.96 crore in Q1 FY27.
Net profit dropped 69% to ₹29.78 lakh from ₹96.76 lakh.
Auditors gave an unmodified report on the unaudited results.

Why it matters

For a nano-cap pharma with a ₹98 crore market cap, a 69% profit crash signals serious near-term pressure on margins or demand. The lack of management commentary means investors have no explanation beyond the bare numbers.

What we’re watching

Whether Q2 shows any recovery or further deterioration.
Any cost or revenue guidance from management in the next call.
Impact on the stock's already thin liquidity at current market cap.

The full read

Mercury Laboratories reported a brutal first quarter. Net profit plunged 69% to ₹29.78 lakh from ₹96.76 lakh a year earlier, on a 12% revenue decline to ₹15.96 crore. The auditors issued a clean report (no qualification) but the absence of management commentary leaves investors guessing. For a nano-cap pharma with a ₹98 crore market cap and a trailing P/E of 20x, this kind of earnings contraction raises real questions about demand and cost control. The next quarter will tell if this was a one-off or the start of a trend.

Primary source: BSE · NSE